By Pablo Erbar

In a letter issued to shareholders earlier this week, BioSig Technologies Inc. (OTCQB: BSGM) provided details regarding their recent developments, as well as market trends and new business opportunities. The medical device company is involved in the development of the PURE EP ™ System, a novel cardiac signal acquisition and display system designed to assist in the treatment and diagnosis of patients displaying abnormal heart rates. BioSig hopes to tackle the unmet need in this area and benefit from the large and growing electrophysiology market in the process.

Thanks to its collaboration with Mayo Clinic, BioSig was featured in three peer-reviewed presentations and publications. The most important was probably the company’s article “Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals”, which was published in the Journal of the American College of Cardiology for Clinical Electrophysiology.

As BioSig advances in the development of a much needed proprietary platform, shareholders can look forward to a growing market with huge opportunities. According to the latest Medical Devices & Diagnostics (MD&D report), global Electrophysiology market revenues are projected to grow by around 10% annually, from $4 billion to an estimated $6 billion by 2020.

Hence, BioSig could reap huge benefits once it is able to deliver the technology needed to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation and Ventricular. In this sense, CEO Gregory Cash stated: “I am extremely pleased with the recent achievements that we have made, and believe that now is an ideal time to provide an in-depth overview of the Company to the investment community.”

Disclosures: The author, Pablo Erbar, holds no interest in any of the securities or entities mentioned above. He has not received compensation for this article, other than from Small Cap Nation. The statements above do not constitute recommendations. The article has been based on publicly available information, and seeks to be unbiased and non-promotional.